Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Joseph Haas

Joseph Haas is a senior writer for Informa’s pharmaceutical news publications, with more than eight years covering the biopharmaceutical industry. He previously worked in public affairs for a real estate trade association and wrote about housing and real estate before moving into healthcare. Most recently, he was managing editor of a newsletter publisher, leading its coverage of the implementation of the Medicare Part D prescription drug benefit. Joe’s areas of expertise include business development, mergers and acquisitions, infectious diseases and liver diseases, including hepatitis C, hepatitis B and non-alcoholic steatohepatitis (NASH). He edits the popular Deal Watch column and enjoys profiling start-up companies. 
Advertisement
Set Alert for Articles By Joseph Haas

Latest From Joseph Haas

Retrophin's Focus Shifts After Phase III PKAN Drug's Failure

Fosmetpantotenate missed all endpoints in a Phase III trial, so Retrophin will shelve the candidate for the rare disease PKAN. Now, the biotech turns focus to Phase III sparsentan in a pair of indications.

Clinical Trials Business Strategies

Vanda Not Ready To Give Up On Jet Lag Indication For Hetlioz Despite CRL

Complete response letter follows July deficiencies letter that made approval seem highly unlikely. Vanda called the setback perplexing and said it plans to continue working to get jet lag disorder added to the Hetlioz label.

Commercial Life Cycle Management

AbbVie’s Post-Humira Strategy Continues Taking Shape With Rinvoq Approval

AbbVie now has both of its Humira successors approved in the US, following April’s Skyrizi approval for psoriasis. But Rinvoq faces stiff competition both within the JAK1 class and in rheumatoid arthritis generally.

Approvals Business Strategies

Deal Watch: Aevi Options AstraZeneca Antibody For Rare Disease

Aevi needs to raise funds first, but hopes to develop MEDI2338 for adult-onset Still’s disease. Also, Alnylam plans to leverage Ironwood’s GI expertise for givosiran in acute hepatic porphyria and Ultragenyx snags option to buy GeneTx.
Deals M & A

Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate

Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.

Deals M & A

Q2 Review: Big Pharmas Weigh In On M&A, Pricing Reform

As earnings season reaches its peak, Merck, Lilly, Gilead, Amgen and Sanofi release their second quarter results. Business development remains a dominant theme. 
Sales & Earnings Biosimilars
See All
Advertisement
UsernamePublicRestriction

Register